Nuvalent Inc
NUVL103.590USD
+2.690+2.67%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
7.49BMarket Cap
LossP/E TTM
More Details of Nuvalent Inc Company
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Nuvalent Inc Info
Ticker SymbolNUVL
Company nameNuvalent Inc
IPO dateJul 29, 2021
CEOPorter (James R)
Number of employees142
Security typeOrdinary Share
Fiscal year-endJul 29
AddressOne Broadway, 14Th Floor
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone18573577000
Websitehttps://www.nuvalent.com/
Ticker SymbolNUVL
IPO dateJul 29, 2021
CEOPorter (James R)
Company Executives of Nuvalent Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-5850.00%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
83.39K
+12340.00%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
58.28K
+10083.00%
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.17K
+10083.00%
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+2647.00%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
+3971.00%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
+2647.00%
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
+2647.00%
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-5850.00%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
83.39K
+12340.00%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
58.28K
+10083.00%
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.17K
+10083.00%
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+2647.00%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
+3971.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
25.06%
Fidelity Management & Research Company LLC
13.59%
Paradigm BioCapital Advisors LP
7.34%
The Vanguard Group, Inc.
7.29%
BlackRock Institutional Trust Company, N.A.
4.36%
Other
42.36%
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
25.06%
Fidelity Management & Research Company LLC
13.59%
Paradigm BioCapital Advisors LP
7.34%
The Vanguard Group, Inc.
7.29%
BlackRock Institutional Trust Company, N.A.
4.36%
Other
42.36%
Shareholder Types
Shareholders
Proportion
Hedge Fund
41.63%
Investment Advisor
37.20%
Investment Advisor/Hedge Fund
19.76%
Individual Investor
2.82%
Private Equity
2.18%
Venture Capital
1.74%
Research Firm
1.33%
Sovereign Wealth Fund
0.52%
Bank and Trust
0.24%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
459
75.24M
104.81%
-2.59M
2025Q3
440
73.50M
109.27%
-4.34M
2025Q2
438
75.09M
113.13%
-1.35M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deerfield Management Company, L.P.
17.99M
25.06%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
9.76M
13.59%
+23.99K
+0.25%
Sep 30, 2025
Paradigm BioCapital Advisors LP
5.27M
7.34%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.60M
6.4%
+80.88K
+1.79%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.13M
4.36%
+88.18K
+2.90%
Sep 30, 2025
Wellington Management Company, LLP
2.30M
3.21%
+724.49K
+45.96%
Sep 30, 2025
Janus Henderson Investors
2.19M
3.05%
+406.09K
+22.78%
Sep 30, 2025
T. Rowe Price Associates, Inc.
1.76M
2.46%
+8.44K
+0.48%
Sep 30, 2025
Shair (Matthew)
1.59M
2.22%
-5.85K
-0.37%
Nov 24, 2025
State Street Investment Management (US)
1.57M
2.19%
+84.47K
+5.67%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Tema Oncology ETF
4.14%
ALPS Medical Breakthroughs ETF
2.65%
Global X Guru Index ETF
1.57%
State Street SPDR S&P Biotech ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
iShares Health Innovation Active ETF
0.82%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
ProShares Ultra Nasdaq Biotechnology
0.65%
Invesco Nasdaq Biotechnology ETF
0.64%
iShares Biotechnology ETF
0.39%
View more
Tema Oncology ETF
Proportion4.14%
ALPS Medical Breakthroughs ETF
Proportion2.65%
Global X Guru Index ETF
Proportion1.57%
State Street SPDR S&P Biotech ETF
Proportion1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.86%
iShares Health Innovation Active ETF
Proportion0.82%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.72%
ProShares Ultra Nasdaq Biotechnology
Proportion0.65%
Invesco Nasdaq Biotechnology ETF
Proportion0.64%
iShares Biotechnology ETF
Proportion0.39%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
